AKR1B1 and type 2 diabetes mellitus: Moreover, in a poly-pharmacology strategy, dual inhibitors of PTP1B and AKR1B1 could be used as multitarget drugs to treat both conditions of insulin resistance and chronic complications associated with T2DM [14].